Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference
February 14, 2022 16:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Mr. Daniel C. Montano, CEO, is recognized as Biotech Entrepreneur of the Year and Dr. Marc Kahn as Medical Professional of the Year by the Nevada Biotechnology & Health Science Consortium
June 17, 2021 13:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, June 17, 2021 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), is proud to announce that Mr. Daniel C. Montano, CEO, and founder of...
Worldwide 3D Cell Culture Industry to 2027 - Advantages of 3D Culture Techniques Over 2D Techniques is Driving Growth
February 09, 2021 07:43 ET
|
Research and Markets
Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "3D Cell Culture Market by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to...
Multiple Sclerosis: Is Therapeutic Angiogenesis a Treatment or Even a Possible Cure?
November 18, 2020 00:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announced that it will give a Webinar broadcast on its potential breakthrough therapy to...
Zhittya Genesis Medicine Announces It Has Been Approved to Initiate Clinical Trials in Mexico for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
October 15, 2020 10:30 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announces that it will initiate clinical trials in Mexico to test a medical hypothesis that...
Zhittya Genesis Medicine Announces a Potential Major Medical Breakthrough for the Treatment of Parkinson’s Disease
September 22, 2020 10:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announces that it will initiate clinical trials to test a medical hypothesis that has been...
COVID-19 Lung Damage: Potential Breakthrough Drug Treatment Disclosed by Zhittya Genesis Medicine in Their Newly Released White Paper
June 17, 2020 10:30 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, June 17, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company)(“Zhittya” or the “Company”), announced that its latest White Paper, which details results on its...
Zhittya Genesis Medicine Releases Latest White Paper Highlighting its Potential Breakthrough Drug Treatment for Chronic Depression
February 19, 2020 12:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), announced that its latest White Paper, which details results on its...
DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update
May 13, 2019 16:48 ET
|
DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollmentCompletion of new cGMP manufacturing run of DM199Conference call with management tomorrow, May 14, 2019 at 7am CT MINNEAPOLIS,...
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
April 30, 2019 16:58 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer...